Call +41-61-926-60-40 Fax +41-61-926-60-49

anti-Lewisy/b hapten (human), mAb (SC104) (preservative free)

AG-20B-6002PF-C100 100 µg INQ
Actions
Select size:

* Required Fields

Amount:
Add to Cart
Call +41-61-926-60-40
Fax +41-61-926-60-49
Contact Us!

Additional Information

Product Data
Synonyms Sialyltetraosylceramide; NCRC37
Properties
Clone SC104
Isotype Mouse IgG1
Source/Host Purified from concentrated hybridoma tissue culture supernatant.
Immunogen/Antigen Tissue cultured colorectal tumor cell lines (C170, C146, Colo205 and JW).
Application ELISA:
Flow Cytometry: (direct and indirect)
Functional Application: Directly induces tumor-specific cell death without the need for immune effector cells by induction of caspase-mediated apoptosis. Optimal concentrations used to induce tumour cell death in vitro and in vivo are between 10-30μg/ml.
Immunocytochemistry: (1-5μg/ml)
Immunohistochemistry: (paraffin sections; 1μg/ml)
Crossreactivity Human
Specificity Recognizes human sialyltetraosylceramide. Does not bind to blood lympocytes, granulocytes, bone marrow progenitor cells, GM1, GD1a, GT1b or sialyl LewisX antigens.
Purity ≥95% (SDS-PAGE)
Endotoxin Content <0.001EU/μg purified protein (LAL test; Lonza).
Concentration Lot dependent
Formulation Liquid. In PBS.
Product Type Monoclonal Antibody
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Download Document Download

Product Description

Membrane glycolipids represent an unexplored source of tumor-associated antigens. Many of these are overexpressed and altered in tumors compared to normal tissue. Research into aberrant glycosylation and over-expression of glycolipids on the surface of the majority of cancers, coupled with a knowledge of glycolipids as functional molecules involved in a number of cellular physiological pathways, has provided a novel area of targets for cancer immunotherapy. Lewis-y/b is a cell surface carbohydrate blood group antigen expressed at very low levels in normal tissue, but often found to be overexpressed on breast, lung, colon and ovarian cancer cells. Clone SC104 recognizes a unique cell surface antigen sialyltetraosylceramide, expressed by 90% of colorectal tumors at all clinical stages. SC104 targets colorectal cancer-associated glycolipids and induces tumor cell death in vitro independently of CDC or ADCC or blockade of known survival signaling pathways. It induces apoptotic cell death and synergizes with chemotherapy in vivo in mice.

Product References

  1. Development of second generation monoclonal antibodies recognising Lewisy/b antigen by anti-idiotypic immunisation: L.G. Durrant, et al.; Hybridoma 12, 647 (1993)
  2. A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis: L.G. Durrant, et al.; Cancer Res. 66, 5901 (2006)
  3. Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy: L.G. Durrant, et al.; Clin. Exp. Immunol. 167, 206 (2012)
No reviews for this product yet.